Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | KMT2A mutant |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05453903 | Phase I | JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT04811560 | Phase I | JNJ-75276617 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia | Recruiting | USA | GBR | FRA | ESP | AUS | 1 |
NCT05521087 | Phase I | Cytarabine + Dexamethasone + Fludarabine + JNJ-75276617 + Pegaspargase + Vincristine Sulfate | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | Withdrawn | USA | 0 |